MD Stock Chart & Stats
$452.49
-$3.12(-0.68%)
―
--
Day’s Range― - ―
52-Week Range$240.12 - $467.41
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$37.71B
Enterprise Value$2.08K
Total Cash (Recent Filing)$328.97M
Total Debt (Recent Filing)$629.72M
Price to Earnings (P/E)12.7
Beta0.36
Next Earnings
Aug 04, 2026EPS Estimate
10.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.06
Shares Outstanding82,121,910
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)2.11
Price to Sales (P/S)0.95
P/FCF Ratio7.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$446.48Price Target Upside― Downside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Cash GenerationOperating and free cash flow have been consistently positive and closely track reported earnings, indicating durable internal funding capacity. Strong cash conversion supports reinvestment, share repurchases, debt paydown and provides a buffer against volume cyclicality, enhancing financial flexibility.
Profitability & ROE RecoveryEarnings and ROE have recovered from prior loss years to mid-to-high teens ROE and positive margins, reflecting improved operating performance. This restoration of profitability increases resilience, supports balance-sheet rebuilding and makes cash generation and capital allocation more sustainable.
Manageable Leverage & Confirmed EBITDA PathReaffirmed EBITDA guidance together with lower DSO, a healthy cash balance and modest net leverage (~1.3x) indicate balanced capital structure and predictable cash flow conversion. This gives management room for strategic investments, partnerships and continued deleveraging over the medium term.
Bears Say
Stagnant Revenue GrowthRevenue has been roughly flat or slightly down over recent periods, constraining scalable margin expansion and making performance more reliant on pricing and efficiency gains. Without sustained volume or service expansion, earnings durability could be vulnerable to reversals in pricing or payor mix.
Dependence On RCM/Admin Fee TailwindsA material portion of recent pricing gains derived from timing-sensitive RCM cash collection and admin fee dynamics. If these tailwinds normalize, pricing and EBITDA growth could slow materially, reducing visibility into sustainable margin improvement and increasing sensitivity to collection cycles.
Rising Labor Costs & Volume PressureHigher clinician compensation (+$9M) combined with modest declines in NICU days compresses margins and reduces revenue leverage. Persistent volume softness or continued wage inflation could erode recent profitability gains and force tighter cost management or slower strategic expansion.
Pediatrix Medical Group News
MD FAQ
What was Pediatrix Medical Group, Inc.’s price range in the past 12 months?
Pediatrix Medical Group, Inc. lowest stock price was $240.12 and its highest was $467.41 in the past 12 months.
What is Pediatrix Medical Group, Inc.’s market cap?
Pediatrix Medical Group, Inc.’s market cap is $37.71B.
When is Pediatrix Medical Group, Inc.’s upcoming earnings report date?
Pediatrix Medical Group, Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 10 days.
How were Pediatrix Medical Group, Inc.’s earnings last quarter?
Pediatrix Medical Group, Inc. released its earnings results on May 05, 2026. The company reported $7.704 earnings per share for the quarter, beating the consensus estimate of $6.653 by $1.051.
Is Pediatrix Medical Group, Inc. overvalued?
According to Wall Street analysts Pediatrix Medical Group, Inc.’s price is currently Undervalued.
Does Pediatrix Medical Group, Inc. pay dividends?
Pediatrix Medical Group, Inc. does not currently pay dividends.
What is Pediatrix Medical Group, Inc.’s EPS estimate?
Pediatrix Medical Group, Inc.’s EPS estimate is 10.35.
How many shares outstanding does Pediatrix Medical Group, Inc. have?
Pediatrix Medical Group, Inc. has 82,121,910 shares outstanding.
What happened to Pediatrix Medical Group, Inc.’s price movement after its last earnings report?
Pediatrix Medical Group, Inc. reported an EPS of $7.704 in its last earnings report, beating expectations of $6.653. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pediatrix Medical Group, Inc.?
Currently, no hedge funds are holding shares in MX:MD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pediatrix Medical Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$446.48 (― Downside)
$446.48 (― Downside)
Blogger Sentiment
Bullish
MX:MD Sentiment 70%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.85%
Trailing 12-Months
Company Description
Pediatrix Medical Group, Inc.
Pediatrix Medical Group, Inc. delivers specialized medical services for newborns, expectant mothers, and pediatric patients across the United States and Puerto Rico. The company offers crucial neonatal care to critically ill or prematurely born infants within hospital units, staffed by expert neonatal subspecialists and advanced practice clinicians. For pregnant individuals and their developing babies, Pediatrix provides comprehensive maternal-fetal medicine services in both clinical and inpatient settings, involving specialists such as maternal-fetal medicine physicians, obstetricians, and genetic counselors. Furthermore, the group delivers pediatric cardiology services, addressing both congenital and acquired heart conditions in patients ranging from the fetal stage through adulthood, under the care of dedicated pediatric cardiologists. Beyond these core areas, Pediatrix extends its expertise to various other pediatric subspecialties, including those requiring intensivists, surgeons, and ophthalmologists, and supplies vital support to hospital departments like emergency rooms and labor and delivery units. Established in 1979 in Sunrise, Florida, and formerly known as MEDNAX, Inc. until its renaming in July 2022, the company managed a network of approximately 2,700 physicians as of February 2022.
MD Stock 12 Month Forecast
Average Price Target
$446.48